CancerNSight™ - A powerful, new tool to facilitate strategic decisions when assessing commercial opportunities in oncology.

• Physician Drivers / Influencers: Which regimen attributes drive and influence first- and second-choice regimen selection?
  

• Patient Types / Segments: What are the physician-identified patient types, and how do they influence regimen selection?
  

• Regimen Benchmarking: How do current regimens perform relative to specific attributes?  What are physician perceptions toward these regimens delivering either superior or inferior levels of performance? 

Who will benefit from CancerNSight™?

Business Development and New Product Planning professionals. CancerNSight™ is for those who need to:

• Understand the forward-thinking rationale of KOLs with the real-world perceptions of practicing community oncologists
  
  
• Utilize a consistent and standardized evaluation approach to compare in-house, in-licensing, or external acquisition candidates to current regimens and regimens in development
  
  
• Manage the communication dialogue with other departments involved in the development process (i.e., clinical development, marketing research, new product forecasting, etc.)
  
  
• Uncover differentiating product attributes or patient types that can be competitively exploited
  
  
• Perform multiple repeat assessments without the luxury of significant resource support

CancerNSight™ also complements other MattsonJack products and services, including CancerMPact® and Oncology Marketing Strategies™. For more information or a demonstration of CancerNSight™, contact:

Steve Clark - steve.clark@mattsonjack.com
East / Southeast U.S.

Mahnoush Haririfar - mahnoush.haririfar@mattsonjack.com
West / Central U.S.

Douglas Lloyd-Fell - douglas.lloydfell@mattsonjack.com
UK / Europe

Naomi Smith - naomi.smith@mattsonjack.com
East / Northeast U.S.